Findings from a phase III clinical trial for advanced lung cancer patients could help oncologists better predict which patients are likely to receive the most benefit from immunotherapy as a first-line treatment based on the unique molecular characteristics of their tumor, according to a new study reported by a global team led by David Carbone of Ohio State University Comprehensive Cancer–Arthur G. James Cancer Hospital and Richard J. Solove Research Institute.
For the first time in decades, more people in the Bronx nearby Montefiore Einstein Comprehensive Cancer Center are being diagnosed with stage 1, versus stage 4 lung cancer.
